Security key
05338F306
Avalo Therapeutics, Inc. - Common Stock, $0.001 par value (AVTX)
CUSIP: 05338F306
Q4 2023 13F Holders as of 31 Dec 2023
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 22,966
- Total 13F value
- $209,366
- Share change
- +22,966
- SEC-reported price per share
- $9.00
- Number of holders
- 12
- Value change
- +$209,366
- Number of buys
- 12
- Shares outstanding
- 57,788,980
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2023
Institutions
12
Top holders
10
AVTX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2024
Avalo Therapeutics, Inc. SEC filings
Avalo Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 05338F306
Recent filing periods:
Ownership snapshot
Top reported holders of AVTX - Avalo Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
0/15
Latest evidence
30 Sep 2023
3/4/5
13F
Highest disclosed value: $397,771
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC has the largest disclosed position value at $397.8K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Disclosed position value
Top 5
ARMISTICE CAPITAL, LLC
$397.8K
ACADIAN ASSET MANAGEMENT LLC
$34K
Virtu Financial LLC
$22K
Baader Bank Aktiengesellschaft
$19.8K
James Archie Harrell Jr.
$19.1K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$397,771
765,828 shares
|
— | 26 Jun 2023 |
| ACADIAN ASSET MANAGEMENT LLC |
13F
Company
|
—
class O/S missing
|
$34,000
283,306 shares
|
— | 30 Sep 2023 |
| Virtu Financial LLC |
13F
Company
|
—
class O/S missing
|
$22,000
185,345 shares
|
— | 30 Sep 2023 |
| Baader Bank Aktiengesellschaft |
13F
Company
|
—
class O/S missing
|
$19,823
184,373 shares
|
— | 30 Sep 2023 |
| James Archie Harrell Jr. |
3/4/5
Chief Commercial Officer
|
—
class O/S missing
|
$19,096
36,766 shares
|
— | 10 Dec 2021 |
| H. Jeffrey Wilkins |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$17,334
33,373 shares
|
— | 10 Dec 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
12
Shares
22,966
Rows available
12
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q4 2025 Across Filers
Q4 2025 holders
84
Q4 2023 holders
12
Holder diff
-72
| Investor | Q4 2025 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q4 2025 value | Q4 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend